Morepen Labs.
Drug Manufacturers - Specialty & Generic · MOREPENLAB
Small CapHealthcareHigh Growth
Sushil Suri
Chairman & Managing Director · Transformational
Company DNA
Performance-Driven
About
Morepen Labs. is a Small Cap company in the Healthcare sector, listed on NSE as MOREPENLAB. With a market cap of ₹2K Cr and revenue of ₹2K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Aggressive market expansion in high-growth segments requires a results-oriented management style. Its strategic mandate: Transitioning from generic manufacturing to high-margin specialty products and R&D-driven growth requires a significant pivot in core business strategy.
FAQ
What kind of company is Morepen Labs.?
Morepen Labs. is a Small Cap Healthcare company (MOREPENLAB) in the High Growth phase with a market cap of ₹2K Cr. It is classified as Performance-Driven in culture.
What is Morepen Labs.'s culture and work environment like?
Morepen Labs. has a Performance-Driven culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Aggressive market expansion in high-growth segments requires a results-oriented management style.
Who leads Morepen Labs.?
Morepen Labs. is led by Sushil Suri (Chairman & Managing Director), a Transformational leader with 33 years of experience.
What are Morepen Labs.'s financials?
Morepen Labs. reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 5.4%. Operating margin: 8%. Market cap: ₹2K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandValue-Champion
LifecycleHigh Growth
Aggressive market expansion in high-growth segments requires a results-oriented management style.
Mandate
Transitioning from generic manufacturing to high-margin specialty products and R&D-driven growth requires a significant pivot in core business strategy.
Transitioning from generic manufacturing to high-margin specialty products and R&D-driven growth requires a significant pivot in core business strategy.
Financials
Revenue FY25₹2K Cr
PAT FY25₹118 Cr
Rev CAGR 5Y5.4%
OPM8%
NPM6.5%
ROE10.2%
ROCE11.4%
P/E21.2
Fwd P/E—
P/B1.8
D/E13.2
Mkt Cap₹2K Cr
Promoter42.7%
Institutional1.4%
Similar Culture
Could You Lead Morepen Labs.?
Take the Genome Benchmark →